Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IV-Globulin SN Inj. 10% in Immune Thrombocytopenia (ITP)
NCT02063789Phase 3Completed
- Sponsor
- GC Biopharma
- Start
- Jun 2014
- Primary completion
- Apr 2016
- Modality
- Biologic
- Countries
- 1
01
Overview
A Phase 3 trial of ALYGLO in immune thrombocytopenia (ITP), sponsored by GC Biopharma. Started Jun 2014; status: completed.
02
Drugs
ALYGLO
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on NCT02063789.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02063789.